Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial.
Mariana S XavierAnete TrajmanCarolina A S SchmaltzFlavia M Sant'annaIvan R MaiaDavid J HadadPedro Emmanuel A A do BrasilValeria C RollaPublished in: BioMed research international (2018)
Efficacy of efavirenz was similar regardless of dosage. Differences regarding safety occurred as mild and transient events, which did not interfere with treatment. Similar efficacy and safety (SSAE) and lower tolerance (minor AE) in the intervention group favour the use of 600 mg efavirenz in patients using rifampicin.
Keyphrases
- randomized controlled trial
- end stage renal disease
- antiretroviral therapy
- hiv infected
- mycobacterium tuberculosis
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- hiv aids
- hiv infected patients
- emergency department
- hiv positive
- pulmonary tuberculosis
- hepatitis c virus
- patient reported outcomes
- brain injury
- patient reported